|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 December 2006, Vol. 108, No. 13, pp. 4292-4294.
CORRESPONDENCE To the editor:Recovery of spermatogenesis after total-body irradiationWe read with interest the paper by Rovo et al,1 who studied spermatogenesis in 39 long-term survivors after allogeneic stem cell transplantation (allo-SCT). Eleven patients had recovery of spermatogenesis. The authors found that a younger age (<25 years) and a non–total-body irradiation (TBI)–based conditioning regimen (CR) were independent factors predicting active sperm production after allo-SCT.
At our institution, male patients gave written consent to be enrolled in a long-term posttransplantation follow-up study, including annual semen analysis (SA). Of the 74 patients enrolled in the study, 40 were male, and 35 underwent a SA. The indication for allo-SCT was chronic myelogenous leukemia (CML; 25 patients), myelodysplastic syndrome (MDS; 5 patients), acute myelogenous leukemia (AML; 3 patients), acute lymphoblastic leukemia (ALL; 1 patient), and chronic lymphocytic leukemia (CLL; 1 patient). Median follow-up after transplantation was 6 years (range, 3-13 years). Most (33) patients (median age, 38 years; range, 17-56 years) received a fractionated TBI (12-13.6 Gy)–based myeloablative stem cell transplantation (MST); 2 patients (aged 39 and 40 years) received a non-TBI nonmyeloablative stem cell transplantation (NST). Follicle-stimulating hormone (FSH) levels ranged from 6 to 46 U/L (median, 19 U/L; reference range, 2-15 U/L), and free testosterone levels ranged from 0.18738 to 0.82586 µM (5.4-23.8 ng/dL) (median, 0.449365 µM [12.95 ng/dL]; reference range, 0.3123-1.041 µM [9-30 ng/dL]) in all patients except for 1, who was treated with a testosterone patch. SA and morphology were assessed as described previously.1,2 Five (14.3%) patients showed evidence of sperm production (3 [9%] MST recipients and the 2 NST recipients; Table 1). Sperm production was associated with younger age at transplantation (
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: John Barrett, Chief, Stem Cell Transplantation Section, Hematology Branch, NHLBI, NIH, Bldg 10, Hatfield CRC, Rm 3-5330, 10 Center Dr MSC 1202, Bethesda, MD 20892-1202; e-mail: barrettj{at}nhlbi.nih.gov. References
Response:Definition of prognostic factors: can the return of spermatogenesis after allogeneic HSCT now be predicted?Gonadal dysfunction and infertility are of major concern in long-term survivors after allogeneic hemopoietic stem cell transplantation (HSCT); several publications have addressed this particular question by trying to identify prognostic factors.1-4 Despite differences in the patient cohorts, the data presented by the National Institutes of Health (NIH) group in this issue of Blood provide similar results to our recent publication.5 This confirms that return of spermatogenesis is associated with young age at transplantation and long follow-up, even in patients conditioned with myeloablative regimens that included TBI.
Savani et al reported sperm production in 5 of 35 male patients after HSCT. From 33 patients conditioned with TBI, 3 showed sperm in their seminal fluid after HSCT. Two patients conditioned with a reduced-intensity regimen had spermatogenesis recovery during their follow-up as well. The authors compared their experience with the results published by the Basel group. The median age of the NIH patients at time of transplantation was older (38 years; range, 17-56 years vs 25 years; range, 5-56 years for the Basel group), and follow-up time was shorter (6 years; range, 3-13 years vs 9 years, range, 2-20 years). Both publications demonstrated that a younger age at transplantation (Savani et al, Reduced-intensity conditioning should not be considered a synonym for fertility recovery, since the return of spermatogenesis also depends strongly on the treatment received before transplantation. For instance, most patients receiving allogeneic HSCT for multiple myeloma or lymphoma are often heavily pretreated with or without autologous HSCT, whereas patients with CML are not. So far, there are no data available on the long-term survivorship of patients conditioned with reduced-intensity modality; therefore, prospective studies should be conducted to address this particular issue. The role of chronic graft-versus-host disease (cGVHD) as alloimmune-mediated damage of gonadal tissue remains an open question, since neither of the studies brought enough evidence for further conclusion. In our cohort, within all patients with some degree of spermatogenesis only 2 had mild cGVHD, and none had a severe presentation. There was statistically a trend in favor of the return of spermatogenesis in patients without chronic GVHD;5 thus, these data suggest that gonadal harm might be determined by extension and severity of cGVHD. In conclusion, both studies remind us that spermatogenesis and fertility are seriously impaired after allogeneic HSCT. However, the current identification of prognostic factors allow for the prediction of the return of sperm production and gives some hope for prospective follow-up of male long-term survivors after allogeneic HSCT. Potential fertility and the related requirement of birth control counseling become an essential matter to be systematically discussed with the long-term survivors. Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Alicia Rovó, Division of Hematology, University Hospital, Basel, Petersgraben 4, CH-4031 Basel, Switzerland; e-mail: rovoa{at}uhbs.ch.
References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
30 years old; P = .04), and a follow-up of 7 years or more (3 of 5 vs 0 of 28; P = .002) in MST recipients. Both NST recipients had spermatogenesis and the highest sperm counts, despite their older age. We did not find a relationship with disease type (P = .874), acute graft-versus-host disease (aGVHD; P = .371), or chronic GVHD (cGVHD; P = .600). In fact, all 5 patients with sperm production had developed cGVHD at some timepoint after transplantation. We also found no relationship between FSH and testosterone levels and spermatogenesis. Mouse models suggest that Leydig cells (producing testosterone) may be a target for GVHD,
7 years and